Document:

AMENDMENT NO. 3 TO LICENSE AND OPTION AGREEMENT

  
 Exhibit 10.4

  
 AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT

  
 THIS AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT
(“the Amendment”) is made and entered into this 16th day of October, 2003 (the “Amendment Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at
7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20 yoido-dong,
Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.” 
  
 RECITALS 
  
 WHEREAS: 
  
 LGLS and GS entered into the License and Option Agreement on October 22, 2002 (“License Effective Date”) and amended said License and Option Agreement by
Amendment No. 1 thereto on November 21, 2002 and Amendment No. 2 thereto on December 6, 2002 (as amended, the “License”); 
  
 The License sets forth the terms by which LGLS grants to GS the sole and exclusive license to use, import, package, sell, and offer for sale Products within the Field in
the Territory, and the exclusive right to use the Trademarks in the Territory in conjunction with the use or sale of the Products; 
  
 The License further sets forth the terms by which LGLS agrees to supply to GS Final Product or Active Pharmaceutical Ingredient (“API”); and 
  
 The Parties now seek to amend the License to conform its terms to the terms by which Final
Product is to be supplied to LGLS under the supply agreement entered into between LGLS and SB PHARMCO PUERTO RICO, INC. and its affiliates (“GLAXO” or “GSK Supply Agreement”) on February 26, 2003 and to revise certain other terms
set forth herein. 
  
 NOW, THEREFORE, in consideration of the premises and mutual
covenants herein contained, the Parties agree as follows: 
  
 1. Section 1.13
shall be deleted in its entirety and replaced with the following revised paragraph: 
  
 “Fully Burdened Cost of Manufacture” means: *****. 
  
 2. Section 1.32 shall be revised to define “Product” as follows: 
  
 “Product” means any compound containing Gemifloxacin as an active ingredient, including API and Final Product. 
  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 1 

 3. A new Section 1.39 shall be inserted to define “Obsolete Materials” as follows: 
  
 “Obsolete Materials” mean any Materials ordered at the
request of GS that will become obsolete as a result of (i) the expiration or termination of the GSK Supply Agreement or (ii) changes in Final Product Specifications and/or the changes in labeling and packaging. 
  
 4. A new Section 1.40 shall be inserted to define “Materials” as follows:

  
 “Materials” mean all material except API used
in the manufacture, storage, and shipment of Final Products. 
  
 5. A new Section
1.41 shall be inserted to define “Long Lead Time Materials” as follows: 
  
 “Long Lead Time Materials” means *****. 
  
 6. A new Section 1.42 shall be inserted, which defines “Second Source Supplier” as follows: 
  
 “Second Source Supplier” means a contract manufacturer, which is retained to produce API in the event of an interruption to LGLS’s
supply, and which has an existing manufacturing plant suitable for the production of API. 
  
 7. A new Section 1.43 shall be inserted, which defines “Adverse Event” as follows: 
  
 “Adverse Event” shall have the meaning; ascribed to the term “adverse drug experience” by the FDA in 21 CFR 310.305(b).

  
 8. A new Section 1.44 shall be inserted, which defines “‘Serious
Adverse Event” as follows: 
  
 “Serious Adverse
Event” shall have the meaning ascribed to the term “serious adverse drug experience” by the FDA in 21 CFR 310.305(b). 
  
 9. A new Section 1.45 shall be inserted to define “Non-Commercial Use” as follows: 
  
 “Non-Commercial Use” means any use of a Product by GS, which is non-commercial in nature, including but not
limited to the distribution of samples, use in clinical trials, pre-Launch compassionate use, and any other use from which GS derives no direct commercial benefit. 
  
 10. Section 5.1 shall be deleted in its entirety and replaced with the following revised text: 
  
 5.1 General. 
  
 (a) Intent of the Parties. The intent of the Parties is that: 
  
 (i) between the Effective Date and until the expiration or
termination of the GSK Supply Agreement, (including any renewal periods thereof, the “Initial Period”), LGLS shall supply to GS, and GS shall exclusively purchase from LGLS, all of GS’s requirements of Final Product according to the
Final Product Specifications, and 
  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 2 

 (ii) following the expiration or termination of the Initial Period and until the
expiration or termination of this Agreement (“Remaining Period”), LGLS shall supply to GS, and GS shall exclusively purchase from LGLS, all of GS’s requirements of API in bulk form according to the API Specifications. 
  
 (b) Terms and Conditions. The terms and conditions by which
LGLS shall supply GS and GS shall purchase from LGLS Final Product or API, as applicable, pursuant to Section 5.l(a) are set forth in this Article 5. 
  
 (c) Manufacturing Site Change. 
  
 (i) Prior to the expiration or termination of the Initial Period, GS shall 
  
 (A) select and contract with a Third Party to conduct final finish and fill operations at a facility
operated by such Third Party during the Remaining Period to produce Final Product from API supplied by LGLS pursuant to Section 5.1(a)(ii); provided, however, that GS shall have no liability to LGLS for costs or damages resulting from the
performance or failure of performance by such Third Party, except to the extent that such costs or damages result from the negligence or willful misconduct of GS, and the agreement with such Third Party shall contain provisions, enforceable by LGLS
as a third party beneficiary, pursuant to which such Third Party agrees to indemnify and hold LGLS harmless from and against claims made against LGLS as a result of the negligence or willful misconduct of such Third Party; and 
  
 (B) obtain all necessary Regulatory Approvals for the
engagement of such Third Party to so produce such Final Product. 
  
 (ii) The commencement of such finish and fill operations at such facility operated by such Third Party in accordance with such Regulatory Approvals so obtained is referred to in this Amendment as the
“Manufacturing Site Change”. 
  
 (iii)
Within 30 days (the “Plan Preparation Period”) following the execution of this Amendment, GS shall, subject to the approval of LGLS, which approval shall not be unreasonably withheld, complete the preparation of a plan (as so completed and
approved, the “Manufacturing Site Change Plan”) for effecting the Manufacturing Site Change and obtaining the Regulatory Approvals for doing so. Promptly following the Plan Preparation Period, GS shall begin implementation of the
Manufacturing Site Change Plan. Until such time as the Manufacturing Site Change occurs, GS shall advise LGLS in writing no less frequently than once per month as to the status of the implementation of the Manufacturing Site Change Plan. 

 
 (iv) GS shall use its best efforts to cause the
Manufacturing Site Change to occur on or before the date of expiration or termination of the Initial Period, and LGLS 

  

 3 

 
shall provide such assistance as GS reasonably requests to cause such Manufacturing Site Change to so occur. 
  
 (d) Assured Inventory Levels. 
  
 If, at any time during the Initial Period, GS and LGLS mutually agree in
their reasonable discretion that it is unlikely that the Manufacturing Site Change will occur on or before the date of expiration or termination of the Initial Period and/or that the actual capacity of the facility contemplated by the Manufacturing
Site Change will be less than its rated capacity and/or that the delivery times of Final Product from such contemplated facility will not be in accordance with the scheduled delivery times previously agreed by GS and LGLS, and that a shortage of
Final Product inventory will thereby occur in respect of projected sales of Final Product following such date as set forth in GS’s then most recent forecast (the amount of such shortage as initially forecasted and adjusted from time to time in
accordance with the procedures set forth below being the “Missed Manufacturing Site Change Shortage”), then LGLS shall use commercially reasonable efforts to undertake any combination of the following actions in order to avoid any such
shortage: 
  
 (i) (A) negotiate with GLAXO to
extend the term of the GSK Supply Agreement and (B) so extend such term, provided that if such term is so extended, then the Initial Period shall be extended for the same length of time as the GSK Supply Agreement is so extended, 
  
 (ii) (A) cause GLAXO to increase its production of Finished
Product during the Initial Period by the amount of the Missed Manufacturing Site Change Shortage and (B) require GS to purchase such Missed Manufacturing Site Change Shortage according to the terms and conditions of this Article 5. 
  
 The Missed Manufacturing Site Change Shortage shall be initially calculated
before June 30, 2004 by forecasting the combined influence of the anticipated delay or supply shortfall and other related factors agreed to by the parties. Thereafter, the Missed Manufacturing Site Change Shortage shall be adjusted from time to time
as LGLS and GS may agree to account for the actual experience with such factors through the passage of time and revisions to the initial assumptions of the Parties regarding the extent and duration of the problem. 
  
 11. Section 5.2 shall be deleted in its entirety and replaced with the following: 

 
 Supply Price. 
  
 (i) The supply price for Final Product provided by LGLS to GS during the
Initial Period until June 30, 2004, shall be equal to ***** percent of LGLS’s Fully Burdened Cost of Manufacture for Final Product supplied thereunder, which shall not be ***** $***** per finished tablet***** $***** per finished tablet. Final
Product provided by LGLS to GS for Non-Commercial Use shall be supplied at its Fully Burdened Cost of Manufacture subject to receipt of appropriate documentation substantiating such Non-Commercial Use and subject to a maximum limit of a commercially
reasonable number of tablets of Finished Product per calendar 

  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 4 

 
quarter; provided, however, that the prices of Final Product shall be in no event ***** the equivalent of $***** per finished tablet ***** than the
equivalent of $***** per finished tablet. 
  
 (ii) The supply
price for Final Product provided by LGLS to GS, following June 30, 2004 and the expiration or termination of any renewal or extension periods to the GSK Agreement, shall be equal to ***** percent of LGLS’s Fully Burdened Cost of Manufacture for
Final Product supplied thereunder, which shall not be ***** $***** per finished tablet; provided, however, that if the Fully Burdened Cost of Manufacture for Final Product ***** $***** per finished tablet, then the supply price for Final Product
provided by LGLS to GS shall be equal to (i) the Fully Burdened Cost of Manufacture for Final Product ***** per finished tablet. The supply price for Final Product provided by LGLS to GS for Non-Commercial Use shall be its Fully Burdened Cost of
Manufacture; provided, however, that the prices of Final Product shall be in no event ***** the equivalent of $***** per finished tablet, ***** $***** per finished tablet, and any and all Final Product so provided for Non-Commercial Use for such
supply price shall be subject to receipt by LGLS of appropriate documentation substantiating such Non-Commercial Use and a maximum limit of a commercially reasonable number of tablets of Finished Product per calendar quarter. 
  
 (iii) The supply price for API provided by LGLS to GS during the Remaining
Period, shall be equal to ***** percent of LGLS’s Fully Burdened Cost of Manufacture for API supplied thereunder, which shall in no event ***** $***** per kg ***** $***** per kg. In addition, (i) if GS purchases more than ***** kg of API in any
calendar year, the $***** supply price shall be reduced by $***** per kg for each additional ***** kg of API purchased in such year in excess of ***** kg, and (ii) the bulk supply price (including the ***** price) shall be renegotiated in good faith
in the event that GS purchases more than ***** kg of API in any 12 month period. In the event that there is an interruption in LGLS’s supply of API for any reason, which continues uncured for more than ***** days, then GS shall have the right
to procure an alternative source of supply for the duration of the interruption (“Second Source”). Notwithstanding the foregoing, GS shall only have the right to procure a Second Source in the event that the interruption arises with
respect to a supply order quantity, which is less than or equal to ***** percent of the quantity anticipated by GS in the most recently updated forecast, immediately preceding the submission of the supply order. LGLS shall have the opportunity to
resume its supply of API upon the elimination or resolution of the events causing the interruption; provided that, however, LGLS shall not resume its role as the exclusive supplier until GS is able to negotiate a termination of its purchase
obligations with the Second Source Supplier. LGLS shall be responsible for any expenses incurred in excess of the price set forth herein, including any expenses related to the termination of any agreement with the Second Source Supplier;
provided, however, that LGLS shall not be responsible for such excess expenses to the extent that such interruption is due to the negligence or willful malfeasance of GS. 
  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 5 

 12. Section 5.4 shall be deleted in its entirety and replaced with the following: 
  
 Specifications. 
  
 5.4.1 LGLS warrants that the Final Product it supplies hereunder during the Initial Period shall meet the Final
Product Specifications, and shall have been manufactured in accordance with all applicable laws and regulations including, without limitation, then-current Good Manufacturing Practice (“cGMP”) standards. LGLS further warrants that the API
comprising Final Product supplied hereunder and the API supplied hereunder in bulk form shall meet the API Specifications. 
  
 5.4.2 If, during the Initial Period, GS requests LGLS to make changes to the Final Product Specifications or the labeling and packaging, then LGLS
shall initiate such changes and GS shall be responsible for the costs incurred by LGLS in making such change, including without limitation, the cost of any change requested in order to maintain the Specifications or packaging and labeling in
conformity with the Final Product’s drug application filed with the FDA, applicable cGMPs, and applicable regulatory acts or legal requirements (including, without limitation, with respect to any of the materials used in the Final Product), not
generally applicable to the manufacture of pharmaceutical products or types of dosage forms (e.g., blister packs or sterile vials). GS retains the right and responsibility for Regulatory Approvals of the Final Product Specifications. 
  
 5.4.3 During the Initial Period, GS shall provide to LGLS, at
GS’s sole cost and expense, camera-ready artwork for the Final Product Specifications as approved for each market, relating to graphics. GS shall bear all artwork costs and expenses incurred as a result of any revision to the Final Product
Specifications. 
  
 5.4.4 During the Initial Period, GS
shall pay for Obsolete Materials in the amount of (i) LGLS’s actual cost of quantities of Obsolete Materials on hand or (ii) if LGLS is required to pay any cancellation fee, the fee that LGLS is required to pay or that was paid to the supplier
for quantities of Obsolete Materials to avoid delivery of any additional quantities of Obsolete Materials, not to exceed the mutually agreed upon value of the Obsolete Materials; provided, however, that to the extent that such Obsolete Materials are
solely attributable to LGLS’s ordering quantities of materials in excess of quantities necessary to fulfill volumes projected in the Nonbinding Forecast, GS shall not be required to pay for such Obsolete Materials. 
  
 13. Section 5.5 shall be deleted in its entirety and replaced with the following paragraphs
set forth below: 
  
 Purchase Order and Forecasting. 

 
 5.5.1 During the Initial Period, GS shall provide to LGLS a
nonbinding projection of the next succeeding ***** months (or such shorter period remaining under the Initial Period) of the anticipated volumes of each Final Product for each market to be ordered by GS pursuant to Section 5.5.3 below. GS shall
provide such projections to LGLS on the first day of each ***** during the Initial Period; provided that GS shall provide to LGLS the first such report no later than the execution of this Amendment No. 3. 
  
 5.5.2 On or before March 1, 2003, GS shall place a firm order for the
amount of Final Product produced to Final Product Specifications which incorporates ***** metric tons of API. 

  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 6 

 
With GS’s permission, LGLS may request that GLAXO order Long Lead Time Materials to fulfill such firm order, subject to GS obtaining any required
Regulatory Approval from the FDA. LGLS shall have no responsibility for lost Long Lead Time Materials due to FDA delays or requirements, and GS shall pay for such Long Lead Time Materials regardless of any FDA delay or requirement relating to the
Final Product. 
  
 5.5.3 All subsequent supply orders for
the delivery of Final Product, submitted prior to the expiration or termination of Initial Period, shall specify the aggregate volumes of Final Product ordered for each market and the delivery date, and each such supply order shall be submitted to
LGLS not less than ninety (90) days prior to the delivery date on which GS has requested shipment pursuant to such supply order; provided that, however, in the event that GS purchases long lead time materials (as defined in Article I and Section
2.4(c) of the GSK Supply Agreement), then such supply orders shall be submitted to LGLS not less than one hundred twenty (120) days prior to the requested delivery date for each such supply order. GS shall submit quarterly supply orders for the
aggregate Final Product volumes for each market, which volumes shall be equivalent to the minimum order quantity for each Final Product in a particular market. The minimum order quantity shall be amount to the lot size of Final Product, equal to
approximately ***** tablets of Final Product. 
  
 5.5.4
LGLS shall not be obligated to produce more than ***** lots of Final Product (totaling approximately ***** tablets) in 2003, unless on or before August 1, 2003, GS submits an additional supply order for Final Product to be manufactured in
2003, for delivery on or before January 1, 2004. Such order shall be for ***** lots of Final Product. 
  
 5.5.5 Upon the commencement of the Remaining Period, GS shall provide to LGLS a non-binding forecast of the quantities of API to be manufactured
during the forthcoming ***** period. This forecast shall be updated by GS on or before ***** of each ***** for the following *****. Within ***** days after the receipt of such forecast, LGLS shall provide to GS a good faith non-binding forecast of
the Fully Burdened Cost of Manufacture of the supply of API forecasted by GS for the next *****. 
  
 5.5.6 Notwithstanding the foregoing, GS shall use its best efforts to provide LGLS with supply orders for the delivery of Final Product or, upon
the commencement of the Remaining Period, API, within the following dates: 
  
 In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of such year; 
  
 In ***** of each year, GS shall provide its supply orders for delivery during the ***** calendar quarter of such year; 
  
 In ***** of each year, GS shall provide its supply orders for delivery during
the ***** calendar quarter of such year; and 
  
 In ***** of each
year, GS shall provide its supply orders for delivery during the ***** calendar quarter of the next year. 
  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 7 

 GS shall issue each supply order to LGLS at least ninety (90) days prior to the delivery date on which GS
has requested LGLS to ship pursuant to each such supply order. 
  
 14. Section 5.6
shall be deleted in its entirety and replaced with the following paragraph: 
  
 Delivery. 
  
 5.6.1 During
the Initial Period, all Final Product shall be shipped FCA GLAXO’s manufacturing facility located at Road 172 Km 9.1, Bo. Certenejas, Cidra, Puerto Rico (as defined in the INCOTERMS, 2000 edition, published by the International Chamber of
Commerce, TCC Publication 560), except with regard to title and risk of loss. LGLS shall arrange for pickup from the facility by a freight forwarder, and title and risk of loss with respect to Final Product shall pass to GS upon pick up of the Final
Product by the carrier or freight forwarder at the facility. LGLS agrees, in accordance with GS’s reasonable written instructions, to arrange for shipping and insurance to such locations as are requested by GS, at the expense of GS. During the
Remaining Period, the Parties agree that API shall be shipped Ex Works (“EXW”), as such term is defined in INCOTERMS 2000, in which case, title and all risks of loss or damage to the API shall remain with LGLS until the API is delivered to
the carrier for shipment at the EXW point, at which time title and all risks of loss or damage shall transfer to GS. During the term of this Agreement, GS shall promptly reimburse LGLS for the cost of any duties incurred in conjunction with the
delivery of the Final Product, and any insurance purchased at the request of GS to cover any risks of loss to GS arising from shipment. 
  
 5.6.2 The initial supply order for Final Product shall be delivered by August 30, 2003, and the delivery date for all subsequent supply orders
shall be the later to occur of (a) the date set forth in the applicable supply order, or (b) the date that is ninety (90) days after LGLS’s receipt of the applicable supply order; provided that, however, the delivery of Product purchased under
the initial Product supply order shall be contingent upon (i) preliminary indication of artwork and NDC number for GS on or before April 4, 2003, (ii) LGLS obtaining NDA approval for the Product from the FDA on or before July 1, 2003; and (iii) GS
delivering final artwork specifications to LGLS on or before July 1, 2003. In the event of any delays regarding the delivery of the initial Product supply order, which arise as a result of the failure to meet any of the foregoing contingencies, LGLS
shall not be obligated to deliver the initial Product purchase order until November 15, 2003. Products shall be delivered in the volumes set forth on the applicable supply order, plus or minus ***** percent (*****%) due to normal production
variances and waste. 
  
 5.6.3 GS shall pay and otherwise
be responsible for all applicable sales taxes in connection with any payment made by GS related to Final Product and/or API by LGLS pursuant to this Agreement. 
  

15. Sections 5.7.1, 5.7.2, 5.7.3, and 5.8.2 shall be amended to insert “or API Specifications, as applicable” immediately following the words “Final
Product Specifications, as applicable to whether Final Product or API is being sold.” 
  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 8 

 16. Sections 5.9.1 and 5.9.2 shall be deleted in their entirety. 
  
 17. Section 5.9.3 shall be amended to delete both references “to GS’s
premises.” 
  
 18. Section 5.9.4 shall be amended to delete “pursuant to
this Article 5” and to replace it with the phrase “pursuant to Section 5.5.2 and delivered to GS pursuant to Section 5.6.2.” 
  
 19. A new Section 5.9.5 shall be added, which shall state as follows: 
  
 During the Initial Period, on or before March 15, 2004, LGLS shall provide to GS an accounting and reconciliation statement, showing the difference
between LGLS’s actual cost of manufacture and supply of the Final Product and the estimated cost invoiced and paid by GS for such manufacture and supply during the period beginning on the Effective Date and continuing until December 31, 2003.
In the event that LGLS’s actual cost for such manufacture and supply exceeds the cost paid by GS during such period, LGLS shall invoice GS for the difference in cost, and GS shall pay such invoice within thirty (30) days after receipt thereof.
In the event that the cost paid by GS for such manufacture and supply during such period exceeds LGLS’s actual cost, LGLS shall credit GS for such difference and apply such credit toward future costs. LGLS shall provide a similar accounting and
reconciliation statement within forty-five (45) days following the expiration or termination of the Initial Period for the period beginning January 1, 2004 and ending on the date of the expiration or termination of the initial Period, and LGLS shall
invoice or reimburse GS for any difference in costs, accordingly. Upon the reasonable request of GS within thirty (30) days following GS’s receipt of an accounting and reconciliation statement under this Section 5.9.5, LGLS shall allow GS to
review LGLS’s documentation to support the accounting and reconciliation statement. Notwithstanding the foregoing, any reconciliation of costs by GS under this Section 5.9.5 shall be subject to the terms and conditions of this Agreement,
including Section 5.2. 
  
 20. Section 5.10 shall be deleted and revised as
follows: 
  
 Release Certificate. LGLS shall provide to GS
with each delivery of Final Product or API a Release Certificate, a Certificate of Analysis, and a Certificate of Compliance signed by a responsible person duly authorized by LGLS or GLAXO to certify the quality of Final Product or API delivered,
each in a form reasonably acceptable to GS. The Release Certificate shall, inter alia, state that the results of the agreed upon testing procedures are in compliance with the Final Product or API Specifications as well as any additional applicable
requirements of Regulatory Authorities. Without limiting the foregoing, unless expressly agreed by the Parties all Final Products or API supplied hereunder shall meet all release criteria established by the FDA or EMEA with respect to such Final
Product or API. 
  
 21. Section 5.11 shall be revised to replace the term
“Final Product” with the term “API.” 
  

 9 

 22. A new Section 5.13 shall be added, along with a new Schedule 10.2 attached hereto, which shall state as follows:

  
 Quality. The Parties have agreed to adopt certain
manufacture and control procedures for API Production, which are set forth in Schedule 10.2 attached hereto. 
  
 23. A new Section 7.1.3 shall be added to state as follows: 
  
 During the Initial Period and prior to the release of Final Products, LGLS shall ensure that the Final Product is tested in accordance with the testing procedures outlined in the Specifications and shall provide to GS
a Certificate of Analysis and batch summary for each batch of the Final Products. 
  
 24. Section 7.4 shall be amended to add to the end of the paragraph the following: 
  
 Upon receipt of any information from GLAXO regarding an Adverse Event, LGLS shall provide, or cause GLAXO to provide, written notice to GS of the occurrence of the Adverse Event as soon as possible, but (i) no later
than twenty-four (24) hours following its receipt of information concerning a possible Serious Adverse Event and (ii) no later than forty-eight (48) hours following its receipt of information of a possible Adverse Event that is not a Serious Adverse
Event. 
  
 25. Section 7.5.5 shall be amended to add the following: 
  
 LGLS shall further have the obligation to immediately notify GLAXO of the
recall, and to cause GLAXO to cooperate with LGLS and GS in administering the recall as the Parties require. 
  
 26. A new Section 7.7 shall be inserted, which states the following: 
  
 Deviation Reports. If during the manufacture or other handling of a Final Product by GLAXO, (i) the process or analytical limits vary from the
typical or established report ranges, release guidelines, or release limits, (ii) Specifications or cGMPs were not followed in the production of the Products, or (iii) the Products fail to conform to Specifications, then LGLS shall provide to GS, or
cause GLAXO to provide to GS, the written report detailing such deviation (“Deviation Report”) prepared by GLAXO, along with all supporting documentation. The Deviation Report shall be attached to, and shall accompany, copies of all
relevant batch records. Any batch or shipment of Final Product that is the subject of a nonconformity or a Deviation Report shall not be shipped to GS, unless otherwise directed by GS, or, if such Final Product was shipped and is held in stock by
GS, then it shall be given a “Hold” or “Unpassed” status and shall not be released into the passed inventory of GS until GS has completed any investigations related to such Products and approved the disposition of the Final
Product. GS shall provide written instructions to LGLS regarding the destruction of any nonconforming Final Products. The cost of destruction and the replacement cost of Final Product shall be LGLS’s responsibility, except to the extent that
the nonconformity was caused by GS’s negligence or willful misconduct. 
  

 10 

 27. A new Section 7.8 shall be inserted, which states the following: 
  
 Product Complaint. LGLS shall provide, or cause GLAXO to provide
prompt written notification to GS of, any complaints of which GLAXO becomes aware relating to any Final Product, including, without limitation, those complaints which implicate GLAXO’s manufacturing or other processes. 
  
 28. A new Section 7.9 shall be inserted, which states the following: 
  
 Regulatory Inspections. During the period that any Glaxo facility is
engaged in the manufacture, packaging, generation, storage, testing, treatment, holding, transportation, distribution, release, or other handling or receiving of Final Product distributed or to be distributed by GS and LGLS is notified that any such
Final Product or facility will be subject to inspection, LGLS shall promptly advise, or cause GLAXO to advise, GS of such inspection. 
  
 29. A new Section 7.10 shall be inserted which states the following: 
  
 Audit and Inspection. During the period that any Glaxo facility is engaged in the manufacture, packaging, generation, storage, testing, treatment,
holding, transportation, distribution, release, or other handling or receiving of Final Products distributed or to be distributed by GS, in the event of an Adverse Event associated with any Final Product or any proposed or actual inspection by the
FDA or other governmental body of such Glaxo facility, or upon request by GS reasonably related to compliance by such Glaxo facility with applicable cGMP standards, LGLS shall promptly arrange for an audit and inspection of the portions of such
GLAXO facility or facilities. All audits shall be conducted by an independent third party, who is selected by LGLS upon the prior written approval of GS and copies of all audit results shall be provided to GS, which results shall be treated as GLAXO
confidential information, pursuant to the Confidential Disclosure Agreement, dated January 24, 2003 and entered into between GLAXO and GS. GS shall be responsible for the cost of all audits conducted as a result of a GS request; provided, however,
if the audit reveals any items of material non-compliance with applicable cGMP standards which is found to have caused such Adverse Event, then LGLS shall be responsible for the payment of all costs of such audit. 
  
 30. A new Section 7.11 shall be inserted, along with a new Schedule 10.3 attached hereto,
which shall state as follows: 
  
 FDA Guaranty. LGLS has
provided to GS a guaranty, attached hereto as Schedule 10.3, that the Products supplied to GS shall not be adulterated or misbranded as of the date of shipment or delivery so as to thereby not be in compliance with the Federal Food, Drug, and
Cosmetic Act. 
  
 31. The phrase “Notwithstanding Section 8.1
hereinabove” should be inserted at the beginning of Section 8.2. 
  
 32.
Sections 8.3, 8.4 and 8.5 shall be deleted and revised as follows: 
  
 8.3
Infringement or Misappropriation of Intellectual Property Rights. If either Party learns of an infringement or threatened infringement of the LGLS Patents or GLAXO Patents, or of a misappropriation of LGLS Know-How, GLAXO Know-How or GS
Know-How, in any 

  

 11 

 
state or country of the Territory in which exists a colorable cause of action for infringement, including patent infringement or provisional rights, or for
misappropriation of trade secrets, it the Party first learning of or discovering the alleged infringement or misappropriation shall promptly notify the other Party in writing and shall provide the other Party with all information reasonably
available to the notifying Party evidencing such infringement or threatened infringement, or of such misappropriation. Upon such notice, the parties shall in good faith consult in an effort to determine whether a reasonably prudent owner or licensee
of intellectual property would institute litigation to enforce the rights at issue in light of all relevant business, economic, and legal factors (including the projected cost of litigation, the likelihood of success on the merits, the probable
amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer or other potential defendant, the possibility of counterclaims against LGLS or GS, the diversion of LGLS’s or GS’s human and economic
resources, the impact of any possible adverse outcome on LGLS or GS and the effect any publicity might have on LGLS’s or GS’s respective reputations and goodwill). 
  
 If GS has standing, GS shall have the right, but not the obligation, to bring, defend and maintain any appropriate suit or
action, or commence settlement negotiations with an alleged infringer, or other potential defendant, for abatement of the infringement or threatened infringement of the LGLS or GLAXO Patents, or of the misappropriation of LGLS Know-How, GLAXO
Know-How or GS Know-How, in any state or country of the Territory, at GS’s sole expense. If GS lacks such standing and requests LGLS to join GS as a party in such suit or action in order for GS to bring such an action, LGLS shall execute all
papers and perform such other acts as may be reasonably requested by GS, at GS’s expense. LGLS shall have the right to participate in any such suit or action using independent counsel, at its sole expense. Any amount recovered by GS as a result
of such suit or action shall first be applied to reimburse each of the Parties, pro rata, for any costs or expenses incurred in bringing, defending and maintaining any such action. The balance (the “Net Recovery”) shall be for the sole
benefit of GS. The Net Recovery shall be considered “Net Sales” with respect to the calendar quarter in which payment to GS was received, and royalties shall accordingly be paid on the amount of the Net Recovery exclusively at the rate(s)
specified in Section 10.3, below. The Net Recovery shall be considered “Net Sales” for purposes of calculating annual Net Sales in accordance with Milestones 3 and 4 in Section 10.2, below. 
  
 If GS fails to initiate suit or action, or commence settlement negotiations
with an alleged infringer, or other potential defendant, within 90 days after first notice of infringement or threatened infringement of the LGLS Patents or the GLAXO Patents, or of a misappropriation of LGLS Know-How, GLAXO Know-How or GS Know-How,
or if having initiated such suit or action it thereafter diligently fails to prosecute such suit or action, LGLS shall have the right, but not the obligation, to bring, defend and maintain any appropriate suit or action for abatement of the
infringement or threatened infringement, or of a misappropriation of LGLS Know-How, GLAXO Know-How or GS Know-How, at LGLS’s sole expense. If LGLS requests GS to join LGLS as a party in such suit or action, GS shall execute all papers and
perform such other acts as may be reasonably requested by LGLS, at LGLS’s expense. GS shall have the right to participate in any such suit or action using independent counsel, at its sole expense. Any amount recovered by LGLS as a result of
such suit or action shall first be applied to reimburse each of the Parties, pro rata, for any costs or expenses incurred in bringing, defending and maintaining 

  

 12 

 
any such action. The balance shall be divided equally between the Parties. The amount of any recovery, net of the amounts necessary to reimburse the Parties
as provided above shall be considered “Net Sales” for purposes of calculating annual Net Sales in accordance with Milestones 3 and 4 in Section 10.2, below. If such recovery is apportioned by the court such that portions thereof are
attributed to infringing activity in different calendar years, or if such apportionment of the recovery can otherwise be readily ascertained, then such apportionment shall govern as to the calendar year(s) in which Net Sales shall be deemed to have
occurred for purposes of such Milestones. Otherwise, the amount of such recovery shall be apportioned equally over the number of calendar years in which infringement was found to have occurred (or in the event of a settlement, over the number of
calendar years in which it was alleged to have occurred). 
  
 8.4 Third Party
Claims. In the event a Third Party asserts a cause of action concerning alleged infringement of the Third Party’s patent by a Party, or in the event a LGLS Patent or GLAXO Patent is the subject of a legal action by a Third Party seeking
declaratory relief, or is subject to an interference, inter partes reexamination or an opposition proceeding instituted by a Third Party, the Parties shall confer and determine whether to defend and how best to control the defense of any such
Third Party action. If the Parties disagree whether a defense should be undertaken, then the party desiring to defend the action or proceeding, if such party has standing, may proceed with such defense, but shall be under no obligation to do so, and
shall pay its own expenses. In the event the Parties agree that the Third Party action should be defended, such defense shall be controlled by GS with respect to the Territory and by LGLS with respect to outside of the Territory. In each such case,
the other Party, if it has standing, shall have the right, at its own expense, to participate in such defense, and to be represented in any such Third Party action by counsel of its choice at its sole discretion. With respect to any such Third Party
action, the Party entitled to control defense shall also have the right to control settlement of such Third Party action; provided, however, that no settlement shall be entered into without the written consent of the other Party, which consent shall
not be withheld unreasonably. In any event, the Party first obtaining knowledge of such Third Party action shall immediately provide the other Party written notice of such and the related facts in reasonable detail, and the Party involved in
defending any such Third Party action or proceeding, shall keep the other Party reasonably informed, in writing, of the progress of any such proceeding. 
  
 8.5 Ownership. Subject to Section 9.2, below, each Party shall have and retain sole and exclusive title to all inventions, discoveries and know-how which are made,
conceived, reduced to practice or generated solely by its employees or agents in the course of or as a result of this Agreement. Each Party shall own an equal undivided interest in all such inventions, discoveries and know-how made, conceived,
reduced to practice or generated jointly by the employees or 
  
 agents of one
Party and the employees or agents of the other Party. Notwithstanding the foregoing, inventorship of patentable inventions shall be in accordance with applicable patent law, and ownership of such patentable inventions shall be determined consistent
with applicable law concerning inventorship and inventors’ obligation to assign. 
  
 8.5.1 Patent Filings for Joint Inventions. The Parties as joint owners of any joint invention shall jointly pay for the prosecution and maintenance of all Patents directed thereto. 

  

 13 

 
All information disclosed to either Party under this Section 8.5.1 shall be deemed to be Confidential Information of the disclosing Party. In the event that
a Party elects not to file or discontinues the prosecution or maintenance of any patents directed to a joint invention, then the other Party may, at its expense, choose to file or continue with the cooperation of the Party choosing not to proceed. A
non-electing Party shall assign the Patents on joint inventions to the other electing Party, subject to a non-exclusive, royalty-free and irrevocable license to the non-electing Party under the Patent for the life of the Patent, unless it is
determined that such an assignment could endanger the patent estate of the electing Party. 
  
 8.5.2 Further Assurances. Each party has or shall obtain appropriate written agreements from all of its respective employees and agents, without limitation and executed at or as of the commencement of
employment or agency, which agreements shall require that all discoveries and inventions conceived or reduced to practice by any individual as a result of the employment or agency shall be promptly reported, fully disclosed, and assigned to the
Party employing or otherwise hiring that individual. In the event a patent application is filed directed to the subject matter of the invention, any such assignment shall be promptly recorded in the appropriate patent office(s). 
  
 33. A new Section 8.6 shall be inserted which states the following: 
  
 8.6 Covenants. In connection with any proceeding subject to Sections 8.3 or 8.4,
neither Party shall enter into any agreement, settlement, or otherwise take any action that results in or constitutes an admission regarding (i) wrongdoing on the part of the other Party, or (ii) the validity, enforceability or absence of
infringement of any intellectual property owned by the other Party, without the prior written consent of the affected Party. The Parties shall cooperate in good faith with each other in connection with any such claim, suit or proceeding and shall
keep each other reasonably informed, in writing, of all material developments in connection with any such claim, suit or proceeding. 
  
 34. Sections 10.3 and 10.4 shall be deleted and revised as follows: 
  
 10.3 Royalty Payments. In addition to the foregoing license fee and milestone payments, commencing on the second anniversary of the first commercial sale of
Product in the Territory, GS shall, subject to Sections 4.3 and 10.4 pay to LGLS royalties on Net Sales in each calendar year at the following rates: 
  

			
	 Annual Net Sales

	  	Royalty Rate

	 on the first $*****
	  	*****
	 over $***** to $*****
	  	*****
	 over $***** to $*****
	  	*****
	 over $*****
	  	*****

  
 The Parties acknowledge that LGLS has
incurred a royalty obligation to GLAXO at a rate of ***** percent of Net Sales for the use of the GLAXO Patents, the GLAXO Know-how and the Trademarks (the “GLAXO Royalty”). During the first two years following first commercial sale

  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 14 

 
of Product in the Territory, GS shall be solely responsible only for payment of the GLAXO Royalty, and all amounts so due shall be paid in accordance with
Sections 10.7-10.11 below. Thereafter (i) GS shall pay royalties to LGLS at the royalty rate(s) set forth above, and (ii) LGLS shall be solely responsible for payment of the GLAXO Royalty and shall indemnify GS and hold GS harmless from and against
any claims by GLAXO as a result of such use by GS of the GLAXO Patents. 
  
 10.4 Term of Royalty Obligations. GS’s obligation to make royalty payments pursuant to Section 10.3 shall commence as provided in Section 10.3 and shall continue until the later of: (i) the expiration of the last to expire of
the LGLS Patents and GLAXO Patents claiming or covering such Product in such country, and (ii) 10 years after first commercial sale of such Product in such country. Following the expiration of GS’s royalty obligations, GS shall retain a
non-exclusive, royalty-free right to use, sell and offer for sale Product in the Territory, using LGLS Know-how and GLAXO Know-how licensed to GS as of the Effective Date and the exclusive right to use the Trademarks for such purposes. GS shall
continue to pay to LGLS a royalty in return for such right to use the Trademark, as provided in Section 11.4, below. 
  
 35. A new Section 13.7.5 shall be inserted, which states the following: 
  
 Obsolete Materials. Upon the end of the Initial Period, GS shall pay for Obsolete Materials in the possession of LGLS in accordance with the terms
of Section 5.4.4 of this Agreement. Upon the request of CTS, LGLS shall deliver such Obsolete Materials to GS and shall transfer the title to such Obsolete Materials to GS, at GS’s expense. For the removal of doubt, this Section 13.7.5 applies
to Obsolete Materials upon the end of the Initial Period and Section 5.4.4 applies to Obsolete Materials during the Initial Period. 
  
 36. Section 13.9 shall be amended to include the following provisions, which shall survive upon expiration or termination of the License: Sections 7.8 and 7.9.

  
 37. Section 14.4 shall be deleted and revised to state as follows: 

 
 Insurance. 
  
 14.4.1. One week prior to the first delivery of Final Product and for a period of five years after the expiration or
termination of this Agreement, each Party shall obtain, and thereafter maintain, at its sole cost and expense, product liability insurance in amounts which are reasonable and customary in the U.S. pharmaceutical industry for companies of comparable
size and activities in a country or countries in the Territory in which Regulatory Approval for sale of a Product is obtained, provided that such reasonable and customary product liability insurance is available in such particular country or
countries in the territory. Such product liability insurance shall insure against all liability arising as a result of activities completed or permitted under this Agreement (including, without limitation, liability for personal injury, physical
injury, and property damage). The Parties expressly agree that, for the period commencing as of the Effective Date and ending as of the first anniversary of the Effective Date, the reasonable and customary amount of product liability insurance shall
be construed to be as follows: primary coverage in the amount of ten million dollars ($10,000,000.00) per occurrence and ten million dollars ($10,000,000.00) in 

  

 15 

 
the annual aggregate. The Parties further agree that these amounts of coverage shall be re-evaluated on an annual basis within thirty (30) days prior to the
anniversary of the Effective Date, and that this Section 14.4.1 shall be amended accordingly as necessary. During the Initial Period, GLAXO shall he named as an additional insured on all policies arising under this Section 14.4.1. 
  
 14.4.2 GS further agrees that it shall obtain and maintain during the
Initial Period general liability insurance in the total coverage amounts of five million dollars ($5,000,000.00) per occurrence and five million dollars ($5,000,000.00) in the aggregate, which shall insure against bodily injury, property damage,
personal injury, and advertising injury claims, which are covered under the policy. LGLS agrees that it shall obtain and maintain during the term of this Agreement general liability insurance in the minimum primary coverage amount of one million
dollars ($1,000,000.00) per occurrence and one million dollars ($1,000,000.00) in the aggregate, which shall insure against bodily injury, property damage, personal injury, and advertising injury claims, which are covered under the policy. The
Parties further agree that these amounts of coverage shall be re-evaluated on an annual basis within thirty (30) days prior to the anniversary of the Effective Date, and that this Section 14.4.2 shall be amended accordingly as necessary. During the
Initial Period, GLAXO shall be named as an additional insured on all policies arising under this Section 14.4.2. 
  
 14.4.3 Each Party shall provide written proof of the existence of such insurance to the other Party promptly upon request. 
  
 38. In Section 15.2, add the phrase “, acts of terrorism” after the word
“war”. 
  
 Except as is expressly provided herein, the
License, along with any and all prior amendments thereto, shall remain in full force and effect. 
  

 16 

 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by the proper
officers as of the Amendment Effective Date. 
  

									
	GENESOFT PHARMACEUTICALS, INC.	 	 	 	LG LIFE SCIENCES, LTD.
					
	By:	 	 /s/ David B. Singer
	 	 	 	By:	 	 /s/ Heung Joon Yang

					
	Its:	 	 Chairman and CEO
	 	 	 	 Its:
	 	 President and CEO

  

 17 

 Schedule 10.2 
  
 Quality Agreement 
  

OBJECTIVE OF THE AGREFMENT 
  
 This agreement covers the manufacture and control procedures for API production made by LG Life Sciences (LGLS) for Genesoft Pharmaceuticals Inc. (Genesoft). Its purpose
is to define the QA requirements and to clarify responsibilities between the parties, and to provide a mechanism for mutual changes agreed to by both parties. 
  

					
	 Item

	  	LGLS Responsibilities

	 	Genesoft Responsibilities

			
	 Raw Materials and Components
	  	*****	 	*****
			
	 Manufacture of Active Pharmaceutical Ingredient
	  	*****	 	*****
			
	 Regulatory Filings
	  	*****	 	*****
			
	 Inspections
	  	*****	 	*****
			
	 Shipping, Packaging, and Storage
	  	*****	 	*****
			
	 Quality Control
	  	*****	 	*****
			
	 Reference Materials
	  	*****	 	*****
			
	 Complaints
	  	*****	 	*****
			
	 Documentation
	  	*****	 	*****
			
	 Samples
	  	*****	 	*****
			
	 Annual Reviews
	  	*****	 	*****
			
	 Management Of Relationships & Communication Strategy
	  	*****	 	*****

  

	*	Confidential information has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. 

  
 18 

 The following table defines the Quality & Technical representatives from both LGLS and Genesoft: 
  

			
	 LGLS Representative

	  	 Genesoft Representative

	 Name: Mr. Yong-Jae Lee
 Title: QA Team Head, General Manager
 LG Life Sciences, Ltd.
 Address: 601 Yongjei-dong, Iksan City
 Chunbuk-do 570-350, Korea
 Tel: 82-(0)63-830-4270 (office)
 82-(0)19-484-1618 (mobile) Fax:
 82-(0)63-830-4204
 e-mail: yjleeb@lgls.co.kr
	  	 Mr. Lewis Michaels
 Genesoft Pharmaceuticals,
Inc.
 7300 Shoreline Court
 South San Francisco, CA
94080
 Tel: (650) 837-1802
 Email:
lmichaels@genesoft.com

  

 19 

 Schedule 10.3 
 Guaranty 
  
 The article
comprising each shipment or other delivery hereafter made by LG LIFE SCIENCES, LTD. (“LGLS”), a corporation organized and existing under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20
yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea, to, or in the order of, GENESOFT PHARMACEUTICALS, INC. (“GS”), a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San
Francisco, CA, USA 94080, is hereby guaranteed, as of the date of such shipment or delivery, to be, on such date, not adulterated or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (the “Act”), as amended, and not
an article which may not, under the provisions of Section 505 or of the Act, be introduced into interstate commerce. 
  
 This Guaranty shall be governed, construed, and interpreted under the laws of the State of California, USA, without regard to conflict of laws principles,
and shall not be assigned by either party except upon the prior written consent of the other party or upon the merger or acquisition of all or part of the assets of GS. This Guaranty shall be binding and inure to the benefit of the successors and
permitted assigns of the Parties, and any assignment not in accordance with this Guaranty shall be void. 
  
 This Guaranty is signed and executed on this the 27th day of February, 2003 (the “Effective Date”) and shall remain in effect until the final
expiration date of the last of the unexpired Final Product, which is supplied or delivered to GS by LG, pursuant to the Supply Agreement between LGLS and SB PHARMCO PUERTO RICO, INC., a corporation organized and existing under the laws of the
Commonwealth of Puerto Rico, having its principal office at Road 172, KM 9.1/Bo. Certenejas, Cidra, Puerto Rico 00739, dated as of February 26, 2003. 
  

			
		
	 By: 
	 	 /s/ Soon-Jae Park

			
	 Printed Name: Soon-Jae Park, Ph.D.

	 Title: Vice President

	 Address:
	 	 LG LIFE SCIENCES, LTD.

	 	 	 LG Twin Tower

	 	 	 20 yoido-dong, Youngdungpo

	 	 	 Seoul, 150-721, Republic of Korea

  

 20Amendment to Employment Agreement

 Exhibit 10.111 
  
 AMENDMENT TO EMPLOYMENT AGREEMENT 
  
 Richard W. Reichow (“Employee”) and Aeolus Pharmaceuticals, Inc., formerly Incara Pharmaceuticals Corporation (the “Company”) hereby agree to amend
the terms of the Employment Agreement dated April 2, 2002, as amended on July 25, 2003, between the Company and the Employee (the “Agreement”) as follows. 
  
 Paragraph 2 of the Agreement is amended by adding the following sentence. 
  
 “After April 30, 2005, the Employee’s employment shall continue in
accordance with the terms of this Agreement on a month-to-month basis, which employment may be terminated at will by the Company upon thirty (30) days written notice. Provided however, if this Agreement is terminated by the Company or if the
Employee’s employment is terminated by the Company for any reason, other than for just cause as defined in Paragraph 7(A)(iii), the Employee shall be entitled to and receive the payments and benefits provided for in Paragraph 7(B) of the
Agreement.” 
  
 Except as set forth above, the provisions of the Agreement,
as amended, shall remain in full force and effect. 
  

					
	 /s/ Richard W. Reichow

	 	 	 	 December 2, 2004

	 Employee’s signature
	 	 	 	 Date

			
	 /s/ James D. Crapo

	 	 	 	 December 2, 2004

	 Aeolus Pharmaceuticals, Inc.
	 	 	 	 Date

	 James D. Crapo
	 	 	 	 
	 Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]